Radiation therapy for gastrointestinal cancers is more precise and easier to tolerate due newer technologies and personalized ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...

Glioblastoma multiforme is an aggressive brain tumor that mainly affects adults. Approximately 30,000 people in the U.S. are ...

TLX101 (131I-iodofalan or 131I-IPA) is a systemically administered targeted radiation therapy that targets L-type amino acid transporter 1, which is typically over-expressed in glioblastoma.

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

The targeted radiation therapy, combined with external beam radiation therapy, demonstrated a median overall survival of 12.4 months from treatment initiation and 32.2 months from initial diagnosis.

Bayer and Vividion Therapeutics, Inc. (Vividion) will present the latest research on their advancing oncology portfolio at the upcoming American Association for Cancer Research (AACR) 2025 Annual ...

Radiation bridging therapy during CAR T-cell manufacturing improves outcomes in R/R LBCL compared to systemic bridging therapy. Axi-cel shows superior overall and complete response rates compared ...

For many cancer patients, side effects from radiation can be debilitating. But a new way of delivering radiation treatment ...

Targeted radionuclide therapy (TRT) is a strategic area of focus for Bayer in oncology precision drug development, building on more than 10 years of real-world experience with a targeted alpha therapy ...